AzTrials
AzTrials

Acute Myocardial InfarctionNCT05266547

Impact of OCT on Outcomes in AMI

An observational study of Acute Myocardial Infarction, run by Beijing Luhe Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This protocol describes a retrospective, single-center study intended to test the impact of optical coherence tomography(OCT) on long term clincical outcomes in patients with acute myocardial infarction(AMI). All the patients will be followed by intracoronary OCT at medium follow-up of 3 years. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Myocardial Infarction
What is being tested?
OCT guided coronary intervention
Type of treatment
Medical device
How many people
1,600 participants
Where
1 siteChina
Study dates
1 Jan 2016to 1 Jan 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: In this retrospective study, all the patients ≥18yesrs with AMI enrolled was devided into 2 groups, the primary endpoint will be major adverse cardiovascular events at least 3 years clinical follow up.

Who may be able to join

  • Age≥18 years old
  • Patients undergo cardiac catheterization and percutaneous coronary intervention(PCI) for AMI(STEMI or NSTEMI) ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction, symptoms onset≤ 24h.NSTEMI was defined as elevated troponin levels and the absence of ST elevation at the time of diagnosis, PCI was performed within 24hours after symtoms onset.
  • Sufficient quality of the OCT recording allowing for CoreLab analysis.

Who cannot join

  • ostial of Left main disease
  • Cardiogenic shock or severe hemodynamic instability
  • Severe renal insufficiency (creatinine clearance ≤30 mL/min)
  • Bacteraemia or septicaemia
  • Severe coagulation disorders
  • Patients with life expectancy less than 1 year
  • Patients who refuse to sign the informed consent form

Trial locations and contacts

1 site in 1 country.

Jincheng Guo, M.D. contact

8610-13521968844

guojcmd@126.com

China1 site, 1 recruiting
  • Beijing Luhe Hospital

    Beijing, 100000

    Jincheng Guo, M.D., 8610-13521968844

    Recruiting

Other trials in China

About this study

Official title: Impact of Optical Coherence Tomography on Long-term Clincal Outcomes in Patients With Acute Myocardial Infarction

This protocol describes a retrospective, single-center study intended to test the impact of optical coherence tomography(OCT) on long term clincical outcomes in patients with acute myocardial infarction(AMI). All the patients will be followed by intracoronary OCT at medium follow-up of 3 years.

Being tested
OCT guided coronary intervention
Keywords
Tomography, Optical Coherence, STEMI, NSTEMI, Major adverse cardiovascular event
Medical subject headings
ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OCT guided coronary interventionDevice

    patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group

Study groups in NCT05266547
Study groupRoleWhat they receive
OCT guided groupNot described
Receives: Device: OCT guided coronary intervention
angiography guided groupNot described
Receives: Device: OCT guided coronary intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. major adverse cardiovascular event

    including cardiovascualr death, myocardial infarction, and target lesion revascularization, target vessel revascularization

    Measured: 3 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2022
  2. Study start1 Jan 2016
  3. Primary completion1 Jan 2023 (estimated)
  4. Study completion1 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
1,600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05266547
Sponsor's protocol ID
BeijngLH
Status last verified
Feb 2022
First submitted
23 Feb 2022
Last updated
4 Mar 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Myocardial Infarction, run by Beijing Luhe Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jincheng Guo, M.D. (8610-13521968844, guojcmd@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

major adverse cardiovascular event (time frame: 3 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in